Paget disease of bone (osteitis deformans)
calcium-bone · Metabolic
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Focal disordered bone remodelling with accelerated turnover producing enlarged, structurally weak, deformed bone. Often asymptomatic (incidental raised ALP or X-ray). Common sites: pelvis, femur, skull, spine, tibia. Usually older adults; may cause bone pain, deformity, fracture, nerve compression (deafness), rarely high-output cardiac failure or osteosarcoma.
Red flags
- Sudden increase in bone pain, soft-tissue mass or rapid growth — exclude osteosarcoma (rare but serious)
- New neurological deficit, cord compression, or hearing loss from skull/spine involvement
- Pathological fracture through pagetic bone
- High-output cardiac failure in extensive polyostotic disease
Assessment
Differential diagnosis
- Metastatic bone disease / myeloma (sclerotic/lytic lesions)
- Primary bone tumour (osteosarcoma — rare Paget complication)
- Osteomalacia / renal osteodystrophy (raised ALP)
- Hyperparathyroid bone disease
- Fibrous dysplasia
Investigations
- Serum ALP (raised — marker of activity and treatment response) with normal calcium/phosphate
- Isolated raised bone ALP with normal LFTs is the classic incidental clue; bone-specific ALP or P1NP if liver disease present
- X-ray of affected area (cortical thickening, coarse trabeculae, bone expansion, lytic/sclerotic mix)
- Radionuclide bone scan to map extent of disease
- Calcium (usually normal; rises if immobilised), vitamin D (replete before bisphosphonate), U&E/eGFR
- Audiometry if skull involvement; MRI/CT if nerve compression or malignant change suspected
Management
- Confirm diagnosis (X-ray +/- bone scan) and assess activity (ALP) and complications
- Ensure vitamin D and calcium replete BEFORE giving IV bisphosphonate (prevents hypocalcaemia)
- Treat if symptomatic (bone pain), or to protect at-risk sites (weight-bearing bone, skull base, pre-surgery, nerve compression)
- Single IV zoledronic acid infusion is treatment of choice — produces prolonged remission
- Analgesia for pain; physiotherapy and orthotics for deformity
- Monitor ALP to judge response and relapse; re-treat if ALP rises and symptoms recur (usually >1 year later)
- Refer for surgery (joint replacement, fracture fixation, nerve decompression) as needed; sudden pain increase → exclude sarcoma
Drugs & doses
Zoledronic acid 5 mg IV single infusion over ≥15 min (treatment of choice; ensure eGFR ≥35 and vitamin D replete)
Calcium 500 mg elemental twice daily + vitamin D for ~10-14 days after zoledronate to prevent hypocalcaemia
Risedronate 30 mg PO od for 2 months — oral alternative if IV contraindicated [verify local]
Paracetamol / NSAID for bone pain
Re-treat with zoledronic acid only on biochemical/symptomatic relapse (usually ≥1 year later)
Disposition
Outpatient endocrine/metabolic bone or rheumatology clinic. Admit only for fracture, cord/nerve compression or suspected malignant change.
Complications & pitfalls
- Deformity (bowing), pathological fracture, secondary osteoarthritis
- Nerve compression (deafness, radiculopathy, basilar invagination)
- Osteosarcoma (<1%) — poor prognosis
- High-output heart failure (extensive disease); hypercalcaemia if immobilised
Exam pearls
- Think Paget in an older patient with an isolated raised ALP and normal calcium/phosphate/LFTs.
- Endocrine Society guidance: a single 5 mg IV zoledronic acid infusion is the treatment of choice and gives durable remission; monitor ALP for response/relapse.
- Always replete vitamin D/calcium before IV bisphosphonate to avoid symptomatic hypocalcaemia.
- ALP (or bone turnover markers) tracks disease activity and response to therapy.
- A fresh focus of pain in long-standing Paget demands imaging to exclude sarcomatous change.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.